Anixa Biosciences, Inc. (NASDAQ:ANIX) CEO Amit Kumar Purchases 43,000 Shares

Anixa Biosciences, Inc. (NASDAQ:ANIX) CEO Amit Kumar bought 43,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was bought at an average price of $2.23 per share, with a total value of $95,890.00. Following the completion of the acquisition, the chief executive officer now owns 559,925 shares in the company, valued at $1,248,632.75. This represents a 8.32 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Anixa Biosciences Trading Up 7.0 %

NASDAQ ANIX opened at $2.28 on Thursday. The stock has a fifty day simple moving average of $2.86 and a 200-day simple moving average of $3.03. The stock has a market cap of $73.37 million, a PE ratio of -5.85 and a beta of 0.82. Anixa Biosciences, Inc. has a twelve month low of $2.07 and a twelve month high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. Research analysts predict that Anixa Biosciences, Inc. will post -0.42 EPS for the current year.

Analysts Set New Price Targets

ANIX has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Anixa Biosciences in a report on Tuesday, November 19th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Tuesday.

Institutional Trading of Anixa Biosciences

Hedge funds have recently modified their holdings of the stock. International Assets Investment Management LLC increased its holdings in Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares during the period. Westside Investment Management Inc. grew its position in shares of Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after buying an additional 21,100 shares in the last quarter. Tyler Stone Wealth Management increased its stake in shares of Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after buying an additional 21,008 shares during the period. Concorde Asset Management LLC acquired a new stake in Anixa Biosciences in the second quarter valued at approximately $31,000. Finally, Virtu Financial LLC purchased a new position in Anixa Biosciences in the third quarter worth approximately $34,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.